Pierrel S.p.A.
PRL.MIDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
ACE527
Diarrhea
Allergoid, allergenic extract of 100% Birch
Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACE527 | Phase 2 | Diarrhea | - | - |
Allergoid, allergenic extract of 100% Birch | Phase 2 | Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma | - | - |
Frequently asked questions
What is in Pierrel S.p.A.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Pierrel S.p.A.'s (PRL.MI) pipeline across Phase 2. Its lead program is ACE527 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pierrel S.p.A.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Pierrel S.p.A. (PRL.MI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRL.MI biotech catalysts?→
Add PRL.MI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pierrel S.p.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.